Compare Inovio Pharmaceuticals Inc (INO) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Under Armour Inc Class A — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Under Armour Inc Class A trades at $7.29 (market cap $3.07B). The key difference: Under Armour Inc Class A is far larger — about 34.4× Inovio Pharmaceuticals Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | UAA | |
|---|---|---|
Market Cap | $89.27M | $3.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $8.14 |
52-Week Low | $1.05 | $4.17 |
Enterprise Value | $60.28M | $4.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Under Armour (UAA) trades at $7.28, down 2.02% amid mixed signals. The stock shows technical bullish momentum with strong moving average support, but faces fundamental challenges including a net loss of $201.27 million in 2025 and negative profit margins. Recent earnings showed Q4 2025 beat expectations but Q1 2026 missed, while the company maintains international growth momentum despite North American weakness.
The outlook remains cautious with analyst consensus price target of $5.96 below current levels. Investment opportunity exists in international expansion and DTC growth, but risks include persistent North American weakness, margin pressure, and negative cash flow trends that could pressure shareholder value in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
